A Multicenter, Randomized, Placebo-Controlled Study of SBC-102 in Patients With Lysosomal Acid Lipase Deficiency

Trial Profile

A Multicenter, Randomized, Placebo-Controlled Study of SBC-102 in Patients With Lysosomal Acid Lipase Deficiency

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Nov 2016

At a glance

  • Drugs Sebelipase alfa (Primary)
  • Indications Wolman disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ARISE
  • Sponsors Alexion Pharmaceuticals; Synageva BioPharma
  • Most Recent Events

    • 11 Nov 2016 Data from this trial presented at The Liver Meeting 2016, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), as per an Alexion Pharmaceuticals media release.
    • 11 Nov 2016 Long-term data published in an Alexion Pharmaceuticals media release.
    • 06 Oct 2016 According to an Alexion Pharmaceuticals media release, long-term data from an open label extension phase (n=65) at 52 weeks were reported in a poster presentation at the 5th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition (WCPGHAN).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top